Director/PDMR Shareholding

RNS Number : 6136C

Genedrive PLC

23 February 2022

 

23 February 2022

genedrive plc

("genedrive" or the "Company")

Director/PDMR Notification

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, makes the following announcement regarding a transaction in the Company's ordinary shares by Matthew Fowler, outgoing Chief Financial Officer.

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated
a.	Name	Matthew Fowler
2.	Reason for the notification
a.	Position/status	Chief Financial Officer
b.	Initial notification /Amendment	Initial
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	genedrive plc
b.	LEI	213800ZYODIRZ87Y4K14
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the Financial instrument, type of instrument Identification code	Ordinary Shares of 1.5p each GB00B1VKB244
b.	Nature of the transaction	Disposal of ordinary shares
c.	Price(s) and volume(s)	Price(s) Volume(s) 17.5p 86,957
d.	Aggregated information · Aggregated volume · Price	86,957 Ordinary Shares 17.5p per Ordinary Share
e.	Date of the transaction	23 February 2022
f.	Place of the transaction	London Stock Exchange, AIM Market (XLON)

For further details please contact:

genedrive plc	[phone]
David Budd: CEO / Matthew Fowler: CFO
Peel Hunt LLP (Nominated Adviser and Joint Broker)	[phone]
James Steel
finnCap (Joint Broker)	[phone]
Geoff Nash / Kate Bannatyne / Alice Lane
Walbrook PR Ltd (Media & Investor Relations)	[phone] or [e-mail]
Paul McManus / Anna Dunphy	[phone] / [phone]

About genedrive plc (http://www.genedriveplc.com) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets and a high throughput SARS-CoV-2 assay. The Company has also recently launched a test to help in the prevention of hearing loss caused by certain antibiotics in neonates. 

 

END

 

 

DSHEASADASXAEFA